Calithera Biosciences (STU:2CB0) Debt-to-Equity : 0.08 (As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Debt-to-Equity?

Calithera Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €1.44 Mil. Calithera Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was €0.13 Mil. Calithera Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2022 was €19.25 Mil. Calithera Biosciences's debt to equity for the quarter that ended in Dec. 2022 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Calithera Biosciences's Debt-to-Equity or its related term are showing as below:

STU:2CB0's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Calithera Biosciences Debt-to-Equity Historical Data

The historical data trend for Calithera Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Debt-to-Equity Chart

Calithera Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.07

0.36

0.08

Calithera Biosciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Equity	Get a 7-Day Free Trial															0.36	-0.86	0.07	0.08	0.08

Competitive Comparison of Calithera Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Calithera Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calithera Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calithera Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Calithera Biosciences's Debt-to-Equity falls into.

Calithera Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Calithera Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.444	+	0.128)	/	19.25
	=	0.08

Calithera Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.444	+	0.128)	/	19.25
	=	0.08

Calithera Biosciences (STU:2CB0) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Calithera Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Calithera Biosciences (STU:2CB0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (STU:2CB0) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080

Website

https://www.calithera.com

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Calithera Biosciences (STU:2CB0) Headlines

No Headlines